To the full analysis
Buyback calculator for Agios Pharmaceuticals
Agios Pharmaceuticals stock: key metrics
AGIOAgios Pharmaceuticals had an operating margin of −873.9% and a return on invested capital (ROIC) of −68.9% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2011 | 100.0% | −76.2% | −108.6% |
| 2012 | −63.5% | −91.6% | −80.1% |
| 2013 | −113.3% | −152.2% | −154.2% |
| 2014 | −53.6% | −82.8% | −81.9% |
| 2015 | −139.9% | −200.8% | −199.1% |
| 2016 | −215.0% | −287.6% | −284.0% |
| 2017 | −580.5% | −745.8% | −731.6% |
| 2018 | 98.5% | −384.0% | −366.6% |
| 2019 | 98.9% | −361.6% | −349.0% |
| 2020 | no data | no data | no data |
| 2021 | no data | no data | no data |
| 2022 | 88.0% | −2,732.1% | −1,627.8% |
| 2023 | 64.6% | −1,459.5% | −1,312.6% |
| 2024 | 88.6% | −1,166.5% | 1,845.9% |
| 2025 | 78.7% | −873.9% | −764.0% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2011 | −37.5% | −9.0% | −12.2% |
| 2012 | −45.8% | −14.6% | −14.7% |
| 2013 | −30.0% | −23.1% | −19.6% |
| 2014 | −12.6% | −14.4% | −10.9% |
| 2015 | −34.1% | −23.5% | −28.0% |
| 2016 | −55.3% | −35.4% | −32.1% |
| 2017 | −83.8% | −48.3% | −51.2% |
| 2018 | −50.3% | −44.6% | −40.3% |
| 2019 | −64.2% | −43.1% | −46.2% |
| 2020 | −81.9% | −33.9% | −38.4% |
| 2021 | no data | −27.9% | no data |
| 2022 | −21.1% | −79.6% | −18.7% |
| 2023 | −43.4% | −30.2% | −37.6% |
| 2024 | 43.7% | −98.6% | 40.5% |
| 2025 | −34.6% | −68.9% | −31.8% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.